T cells in combination with antitumor-directed B-cell-derived factors (e.g. immunoglobulins - Igs) activate tumor inhibitory responses sustained by newly recruited innate immune cells and effectors cytotoxic T lymphocytes (CTLs); all these cellularsoldiers comprise an army that can induce a tumor rejection. The gene discussed is CUBN; the disease is neoplasm.